RDB07567 - pGL4-phBCL2

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pGL4-phBCL2 (#RDB07567)

Promoter collection, Human BCL2 promoter

Alternative name	U2644(2022)-4
Clone info.	PCR amplified human BCL2 promoter sequence was inserted into a firefly luciferase vector. Cloned fragment: 63320698 to 63319352(NC_000018.10); relatively -1318 to +29, where +1 corresponds to 1 nt of NM_000633.2.
Comment	PCR cloning, forward primer: actcacacggccagaaagg; reverse primer: tcgattcccagacttctgct.
Vector backbone	pGL4.10 [Luc2] (Plasmid)
Selectable markers	Amp^r
Gene/insert name	Human B-cell CLL/lymphoma 2 genomic DNA
Depositor\|Developer	DNA Bank, \| Kishikawa, Shotaro \|

Remarks, protocol and/or map (pdf)	RDB07567.pdf

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link]

Terms and conditions for distribution In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Information of Request for Distribution.[link]
Terms and conditions for distribution	In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件	謝辞の表明を必要とする。 MTAに書く付加的使用条件：本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07567	pGL4-phBCL2	DNA solution

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pGL4-phBCL2 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07567).

Reference section:

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB07567_A5A6.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: pGL4-4174F Sequence file: RDB07567_A5A6a.seq
>07567_07567_A5A6_pGL4-4174F_C01_07.ab1 1 GCTGGGGGTC AGACATTTCT CTGGCCTACT GGCCGGTACC TGAGCTCGCT AGCCTCGAGG 61 ATACTCACAC GGCCAGAAAG GGTCCAGGCG GTTCCCGGCG CTTTTCCAGC CCTTGTTTTC 121 ATGGCGCACC CTCCCGCCAG CCGCCCCCCT CCGCACTCCG TCGTCCGCCC GGCCCGGCCG 181 CGTGCGGTTC CCCGGGAGCC CCCACCCCGT CGCGGACCCC AGCGACCACC AAGTCCGCAC 241 GCGGCCTGCC GCAGGCCTGA GCAGAAGGCC CCGCGCACAC CCACCGCGCC GCGGCCGCGC 301 GGGAGGCCTG TGCCGCCCGC GCCACCCACT GGCCGGGCCC CGCGGGCGCA GCGGAGCGGG 361 CGGGTGGCCG GCCCGGACGC GCCCTCCCCG GCCGCGGCCC CGCGCGCCAT GTGCCCCCGG 421 CGGGACGCGC CACTCCCGGG CCTGCCGCGG CGCCTTTAAC CCGGGCCAGG GAGCGGGGCG 481 GAGGGGGCGG TCGGGTGGCT CAGAGGAGGG CTCTTTCTTT CTTCTTTTTT TGAATGAACC 541 GTGTGACGTT ACGCACAGGA AACCGGTCGG GCTGTGCAGA GAATGAAGTA AGAGGACAGG 601 CACCACAGCC CCGCTCCCGC CCCCTTCCTC CCGCGCCCGC CCCTCCGCGC CGCCTGCCCG 661 CCCGCCCGCC GCGCTCCCGC CCGCCGCTCT CCGTGGCCCC GCCGCGCTGC CGCCGCCGCC 721 GCTGCCAGCG AAGGTGCCGG GGCTCCGGGC CCTCCCTGCC GGCGGCCGTC AGCGCTCGGA 781 GCGGGCTGCG CGGCGGGAGC TCCGGGAGGC GGCCGTAGCC AGCGCCGCCG CGCAGGACCA 841 GGAGGAGGAG AAAGGGTGCG CAGCCCGGAG GCGGGGGTGC GCCGGTGGGG GTGCAGCGGA 901 AGAGGGGGGT CCAGGGGGGG GAGAACTTCC GTAGCAGTCA TCCCTTTTTA GGGAAAAGAG 961 GGGAAATGTT AAAACCCTCC CCCAACCACC TTCCTTTCTT CCCCACCCCT TCGCCGGCAC 1021 CAACACACAG CCGCGGGGCC TTCCTAGCCG CTTCGGAGCA CCGGGCCGGG GCTCAGGGCC 1081 GGCCGGTTCC TGGCCCTTTC CAATTTATTC CCAGGCCAGG CCGTTTTTTC CGGGAAAATG 1141 GCCATTGGCC TTGGTTTCCG GAAAGGTTTT AAATCTCAGG AAAGCAGGGG GCATTCCCCC 1201 TGGGGCCCTC TCTCAGT //
Primer: pGL4-136R Sequence file: RDB07567_A5A6b.seq
>07567_07567_A5A6_pGL4-136R_D01_10.ab1 1 GCGGCCTTTA AGTTTTTTGG CATCTTGCAT GGTGGCTTTA CCAACAGTAC CGGATTGCCA 61 AGCTTGGCCG CCGAGGCCAG ATCTTGATTC GATTCCCAGA CTTCTGCTTC ACAGAAATGT 121 CAATCCGCAG GAATCCCAAC CGGAGATCTC AAGAGCTCGA GAAAAAAAAA AGGCAGCGGC 181 GGCGGCAGAT GAATTACAAT TTTCAGTCCG GTATTCGCAG AAGTCCTGTG ATGTTTTCCC 241 CTTCTCGGCA ATTTACACGC GCGCACACAC GCGCGGGCAC AGGCATGAAT CTCTATCCAC 301 GGGACCGCTT CACGCCTCCC CAGGAGAGAG ACAGGGGAGA GGGGACGATG AAGGAGCCGG 361 GGACGGAGGC AGGAATCCTC TTCTGATTAA ACTCCGAACA GCAAATGCAT TTTCCGAAAA 421 GCTGCTGGAT AAATGAAGGC AGGACGCGCC TGGCCCGCCG GTGCCGAGCG CTAGAAGCCC 481 GCGCTGTGTG TGGTGCGGCG AGGGGTGGGG AGAAGGAGGT GGTGGGGGAG GGTTTTATTT 541 TTTCCCTCTT TTCCTAAAAA GGATGACTGC TACGAAGTTC TCCCCCCTGG ACCCCCTCTT 601 CCGCTGCACC CCACCGGCGC ACCCCGCCTC CGGGCTGCGC ACCCTTTCTC CTCCTCCCTG 661 GTCCTGCGCG GCGGCGCTGG CTACGGCCGC CTCCCGGAGC TCCCGCCGCG CAGCCCGCTC 721 CGAGCG //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

Resource search

Link

Other resources in our bank

human B-cell CLL/lymphoma 2

External Database
Human B-cell CLL/lymphoma 2

Reference sequence